ANTI-CLDN4/ANTI-CD137 BISPECIFIC ANTIBODY
An object of the present invention is to provide an anti-CLDN4/anti-CD137 bispecific antibody usable in treatment of cancer.An anti-CLDN4/anti-CD137 bispecific antibody produced using an anti-CLDN4 antibody binding to CLDN4 and an anti-CD137 antibody binding to CD137 had agonistic activity for CD137...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | SHIRAI, Hiroki SASAKI, Hiroki YURI, Masatoshi CHIWAKI, Fumiko YAGI, Shigenori KOMATSU, Masayuki SATAKE, Yoshiki TENDA, Yoshiyuki HIRAYAMA, Kazunori |
| description | An object of the present invention is to provide an anti-CLDN4/anti-CD137 bispecific antibody usable in treatment of cancer.An anti-CLDN4/anti-CD137 bispecific antibody produced using an anti-CLDN4 antibody binding to CLDN4 and an anti-CD137 antibody binding to CD137 had agonistic activity for CD137, promoted production of interferon γ by a T cell, and exhibited cytotoxic activity against a cancer cell expressing CLDN4 on a cell surface thereof. Besides, it was shown that the anti-CLDN4/anti-CD137 bispecific antibody can be safely administered to monkeys. Therefore, the anti-CLDN4/anti-CD137 bispecific antibody is usable in treatment of human cancer. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US2024209108A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US2024209108A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US2024209108A13</originalsourceid><addsrcrecordid>eNrjZNB09Avx1HX2cfEz0YcwXQyNzRWcPIMDXJ093TydFUCiTv4ukTwMrGmJOcWpvFCam0HZzTXE2UM3tSA_PrW4IDE5NS-1JD402MjAyMTIwNLQwMLR0Jg4VQB_LSS_</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>ANTI-CLDN4/ANTI-CD137 BISPECIFIC ANTIBODY</title><source>esp@cenet</source><creator>SHIRAI, Hiroki ; SASAKI, Hiroki ; YURI, Masatoshi ; CHIWAKI, Fumiko ; YAGI, Shigenori ; KOMATSU, Masayuki ; SATAKE, Yoshiki ; TENDA, Yoshiyuki ; HIRAYAMA, Kazunori</creator><creatorcontrib>SHIRAI, Hiroki ; SASAKI, Hiroki ; YURI, Masatoshi ; CHIWAKI, Fumiko ; YAGI, Shigenori ; KOMATSU, Masayuki ; SATAKE, Yoshiki ; TENDA, Yoshiyuki ; HIRAYAMA, Kazunori</creatorcontrib><description>An object of the present invention is to provide an anti-CLDN4/anti-CD137 bispecific antibody usable in treatment of cancer.An anti-CLDN4/anti-CD137 bispecific antibody produced using an anti-CLDN4 antibody binding to CLDN4 and an anti-CD137 antibody binding to CD137 had agonistic activity for CD137, promoted production of interferon γ by a T cell, and exhibited cytotoxic activity against a cancer cell expressing CLDN4 on a cell surface thereof. Besides, it was shown that the anti-CLDN4/anti-CD137 bispecific antibody can be safely administered to monkeys. Therefore, the anti-CLDN4/anti-CD137 bispecific antibody is usable in treatment of human cancer.</description><language>eng</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240627&DB=EPODOC&CC=US&NR=2024209108A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240627&DB=EPODOC&CC=US&NR=2024209108A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>SHIRAI, Hiroki</creatorcontrib><creatorcontrib>SASAKI, Hiroki</creatorcontrib><creatorcontrib>YURI, Masatoshi</creatorcontrib><creatorcontrib>CHIWAKI, Fumiko</creatorcontrib><creatorcontrib>YAGI, Shigenori</creatorcontrib><creatorcontrib>KOMATSU, Masayuki</creatorcontrib><creatorcontrib>SATAKE, Yoshiki</creatorcontrib><creatorcontrib>TENDA, Yoshiyuki</creatorcontrib><creatorcontrib>HIRAYAMA, Kazunori</creatorcontrib><title>ANTI-CLDN4/ANTI-CD137 BISPECIFIC ANTIBODY</title><description>An object of the present invention is to provide an anti-CLDN4/anti-CD137 bispecific antibody usable in treatment of cancer.An anti-CLDN4/anti-CD137 bispecific antibody produced using an anti-CLDN4 antibody binding to CLDN4 and an anti-CD137 antibody binding to CD137 had agonistic activity for CD137, promoted production of interferon γ by a T cell, and exhibited cytotoxic activity against a cancer cell expressing CLDN4 on a cell surface thereof. Besides, it was shown that the anti-CLDN4/anti-CD137 bispecific antibody can be safely administered to monkeys. Therefore, the anti-CLDN4/anti-CD137 bispecific antibody is usable in treatment of human cancer.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZNB09Avx1HX2cfEz0YcwXQyNzRWcPIMDXJ093TydFUCiTv4ukTwMrGmJOcWpvFCam0HZzTXE2UM3tSA_PrW4IDE5NS-1JD402MjAyMTIwNLQwMLR0Jg4VQB_LSS_</recordid><startdate>20240627</startdate><enddate>20240627</enddate><creator>SHIRAI, Hiroki</creator><creator>SASAKI, Hiroki</creator><creator>YURI, Masatoshi</creator><creator>CHIWAKI, Fumiko</creator><creator>YAGI, Shigenori</creator><creator>KOMATSU, Masayuki</creator><creator>SATAKE, Yoshiki</creator><creator>TENDA, Yoshiyuki</creator><creator>HIRAYAMA, Kazunori</creator><scope>EVB</scope></search><sort><creationdate>20240627</creationdate><title>ANTI-CLDN4/ANTI-CD137 BISPECIFIC ANTIBODY</title><author>SHIRAI, Hiroki ; SASAKI, Hiroki ; YURI, Masatoshi ; CHIWAKI, Fumiko ; YAGI, Shigenori ; KOMATSU, Masayuki ; SATAKE, Yoshiki ; TENDA, Yoshiyuki ; HIRAYAMA, Kazunori</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US2024209108A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2024</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>SHIRAI, Hiroki</creatorcontrib><creatorcontrib>SASAKI, Hiroki</creatorcontrib><creatorcontrib>YURI, Masatoshi</creatorcontrib><creatorcontrib>CHIWAKI, Fumiko</creatorcontrib><creatorcontrib>YAGI, Shigenori</creatorcontrib><creatorcontrib>KOMATSU, Masayuki</creatorcontrib><creatorcontrib>SATAKE, Yoshiki</creatorcontrib><creatorcontrib>TENDA, Yoshiyuki</creatorcontrib><creatorcontrib>HIRAYAMA, Kazunori</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>SHIRAI, Hiroki</au><au>SASAKI, Hiroki</au><au>YURI, Masatoshi</au><au>CHIWAKI, Fumiko</au><au>YAGI, Shigenori</au><au>KOMATSU, Masayuki</au><au>SATAKE, Yoshiki</au><au>TENDA, Yoshiyuki</au><au>HIRAYAMA, Kazunori</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>ANTI-CLDN4/ANTI-CD137 BISPECIFIC ANTIBODY</title><date>2024-06-27</date><risdate>2024</risdate><abstract>An object of the present invention is to provide an anti-CLDN4/anti-CD137 bispecific antibody usable in treatment of cancer.An anti-CLDN4/anti-CD137 bispecific antibody produced using an anti-CLDN4 antibody binding to CLDN4 and an anti-CD137 antibody binding to CD137 had agonistic activity for CD137, promoted production of interferon γ by a T cell, and exhibited cytotoxic activity against a cancer cell expressing CLDN4 on a cell surface thereof. Besides, it was shown that the anti-CLDN4/anti-CD137 bispecific antibody can be safely administered to monkeys. Therefore, the anti-CLDN4/anti-CD137 bispecific antibody is usable in treatment of human cancer.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_US2024209108A1 |
| source | esp@cenet |
| subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | ANTI-CLDN4/ANTI-CD137 BISPECIFIC ANTIBODY |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T17%3A56%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=SHIRAI,%20Hiroki&rft.date=2024-06-27&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS2024209108A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |